Therapeutic Cell Engineering with Surface-conjugated Synthetic Nanoparticles

Overview

Journal Nat Med

Specialties General Medicine
Molecular Biology

Date 2010 Aug 17

PMID 20711198

Citations 277

Authors

Matthias T Stephan

James J Moon

Soong Ho Um

Anna Bershteyn

Darrell J Irvine

Affiliations

Soon will be listed here.

Abstract

A major limitation of cell therapies is the rapid decline in viability and function of the transplanted cells. Here we describe a strategy to enhance cell therapy via the conjugation of adjuvant drug-loaded nanoparticles to the surfaces of therapeutic cells. With this method of providing sustained pseudoautocrine stimulation to donor cells, we elicited marked enhancements in tumor elimination in a model of adoptive T cell therapy for cancer. We also increased the in vivo repopulation rate of hematopoietic stem cell grafts with very low doses of adjuvant drugs that were ineffective when given systemically. This approach is a simple and generalizable strategy to augment cytoreagents while minimizing the systemic side effects of adjuvant drugs. In addition, these results suggest therapeutic cells are promising vectors for actively targeted drug delivery.

Citing Articles

Applications of Gene Editing and Nanotechnology in Stem Cell-Based Therapies for Human Diseases.

Bolideei M, Barzigar R, Gahrouei R, Mohebbi E, Haider K, Paul S Stem Cell Rev Rep. 2025; .

PMID: 40014250 DOI: 10.1007/s12015-025-10857-0.

Ultrasound and Photoacoustic Imaging of Nanoparticle-Engineered T Cells and Post-Treatment Assessment to Guide Adoptive Cell Immunotherapy.

Kubelick K, Kim J, Kim M, Huang X, Wang C, Song S ACS Nano. 2025; 19(6):6079-6094.

PMID: 39908484 PMC: 11841050. DOI: 10.1021/acsnano.4c12929.

Self-assembled lipid-based nanoparticles for chemotherapy against breast cancer.

Liu S Front Bioeng Biotechnol. 2024; 12:1482637.

PMID: 39534673 PMC: 11555772. DOI: 10.3389/fbioe.2024.1482637.

Interleukin-12 Delivery Strategies and Advances in Tumor Immunotherapy.

Dong C, Tan D, Sun H, Li Z, Zhang L, Zheng Y Curr Issues Mol Biol. 2024; 46(10):11548-11579.

PMID: 39451566 PMC: 11506767. DOI: 10.3390/cimb46100686.

Polymers as Efficient Non-Viral Gene Delivery Vectors: The Role of the Chemical and Physical Architecture of Macromolecules.

Khan M Polymers (Basel). 2024; 16(18).

PMID: 39339093 PMC: 11435517. DOI: 10.3390/polym16182629.

References

Lu J, Giuntoli 2nd R, Omiya R, Kobayashi H, Kennedy R, Celis E . Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes. Clin Cancer Res. 2002; 8(12):3877-84. View

Prescher J, Dube D, Bertozzi C . Chemical remodelling of cell surfaces in living animals. Nature. 2004; 430(7002):873-7. DOI: 10.1038/nature02791. View

Reddy S, van der Vlies A, Simeoni E, Angeli V, Randolph G, ONeil C . Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat Biotechnol. 2007; 25(10):1159-64. DOI: 10.1038/nbt1332. View

Thompson J, Lee D, COX W, Lindgren C, Collins C, Neraas K . Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial. Cancer Res. 1987; 47(15):4202-7. View

Weissleder R, Kelly K, Sun E, Shtatland T, Josephson L . Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol. 2005; 23(11):1418-23. DOI: 10.1038/nbt1159. View

Reichardt W, Durr C, von Elverfeldt D, Juttner E, Gerlach U, Yamada M . Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation. J Immunol. 2008; 181(7):4770-9. PMC: 2881823. DOI: 10.4049/jimmunol.181.7.4770. View

Kirpotin D, Drummond D, Shao Y, Shalaby M, Hong K, Nielsen U . Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 2006; 66(13):6732-40. DOI: 10.1158/0008-5472.CAN-05-4199. View

Bernstein I, Boyd R, van den Brink M . Clinical strategies to enhance posttransplant immune reconstitution. Biol Blood Marrow Transplant. 2008; 14(1 Suppl 1):94-9. PMC: 2744216. DOI: 10.1016/j.bbmt.2007.10.003. View

Rubinstein M, Kovar M, Purton J, Cho J, Boyman O, Surh C . Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci U S A. 2006; 103(24):9166-71. PMC: 1482584. DOI: 10.1073/pnas.0600240103. View

10.

Wallace A, Kapoor V, Sun J, Mrass P, Weninger W, Heitjan D . Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin Cancer Res. 2008; 14(12):3966-74. PMC: 2491721. DOI: 10.1158/1078-0432.CCR-08-0356. View

11.

Dimos J, Rodolfa K, Niakan K, Weisenthal L, Mitsumoto H, Chung W . Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science. 2008; 321(5893):1218-21. DOI: 10.1126/science.1158799. View

12.

Davis M, Chen Z, Shin D . Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008; 7(9):771-82. DOI: 10.1038/nrd2614. View

13.

Sahaf B, Heydari K, Herzenberg L, Herzenberg L . Lymphocyte surface thiol levels. Proc Natl Acad Sci U S A. 2003; 100(7):4001-5. PMC: 153037. DOI: 10.1073/pnas.2628032100. View

14.

Dinauer N, Balthasar S, Weber C, Kreuter J, Langer K, von Briesen H . Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes. Biomaterials. 2005; 26(29):5898-906. DOI: 10.1016/j.biomaterials.2005.02.038. View

15.

Gattinoni L, Zhong X, Palmer D, Ji Y, Hinrichs C, Yu Z . Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med. 2009; 15(7):808-13. PMC: 2707501. DOI: 10.1038/nm.1982. View

16.

Mackinnon S, Thomson K, Verfuerth S, Peggs K, Lowdell M . Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells. Blood Cells Mol Dis. 2007; 40(1):63-7. DOI: 10.1016/j.bcmd.2007.07.003. View

17.

Berger C, Berger M, Hackman R, Gough M, Elliott C, Jensen M . Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood. 2009; 114(12):2417-26. PMC: 2746471. DOI: 10.1182/blood-2008-12-189266. View

18.

Dhar S, Gu F, Langer R, Farokhzad O, Lippard S . Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A. 2008; 105(45):17356-61. PMC: 2582270. DOI: 10.1073/pnas.0809154105. View

19.

Treisman J, Hwu P, Minamoto S, Shafer G, Cowherd R, Morgan R . Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen. Blood. 1995; 85(1):139-45. View

20.

Overwijk W, Tsung A, Irvine K, Parkhurst M, Goletz T, Tsung K . gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med. 1998; 188(2):277-86. PMC: 2212458. DOI: 10.1084/jem.188.2.277. View